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Understanding the conformational changes associated with the binding of small ligands to their 
biological targets is a fascinating and meaningful question in chemistry, biology and drug discovery. 
One of the most studied and important is the so-called “DFG-flip” of tyrosine kinases. The conserved 
three amino-acid DFG motif undergoes an “in to out” movement resulting in a particular inactive 
conformation to which “type II” kinase inhibitors, such as the anti-cancer drug Imatinib, bind. Despite 
many studies, the details of this prototypical conformational change are still debated. Here we combine 
various NMR experiments and surface plasmon resonance with enhanced sampling molecular dynamics 
simulations to shed light into the conformational dynamics associated with the binding of Imatinib to 
the proto-oncogene c-Src. We find that both conformational selection and induced fit play a role in the 
binding mechanism, reconciling opposing views held in the literature. Moreover, an external binding 
pose and local unfolding (cracking) of the aG helix are observed.
Molecular recognition plays a fundamental role in all biological processes. Understanding it in atomic detail is of 
great importance as it could lead to more effective and less toxic drugs. Most of the current knowledge stems from 
high-resolution crystal structures, time resolved spectroscopy and atomistic molecular dynamics simulations, 
which made clear that molecular recognition is a very dynamical event. Both the ligand and the target can change 
shape to achieve a tight fit. The two limiting mechanisms describing this dynamical adaptation, the “induced fit”1 
hypothesis and the “conformational selection” hypothesis2,3 have been now observed in different systems and it is 
increasingly clear that both play a role4,5.
An interesting case, which has recently attracted much attention, is that of the powerful anti-leukemic drug 
Imatinib (also know as Gleevec), that revolutionized cancer treatment since its discovery in 20016. The drug has 
a 2300-fold lower inhibitory power towards the c-Src tyrosine kinase (TK)7 relative to its specific target, the c-Abl 
tyrosine kinase8,9, despite the high sequence identity (47%). Both conformational selection and induced fit effects 
have been invoked to justify such a dramatic difference. Imatinib binds to an inactive conformation, where the 
aspartate (Asp404 in c-Src) of the conserved Asp-Phe-Gly motif (DFG), located at the N-terminal end of the long 
activation loop (A-loop), points outwards from the ATP cavity10 (Fig. 1). Thus, at first, the selectivity of Imatinib 
towards c-Abl has been attributed to the inability of c-Src of assuming this peculiar “DFG-out” conformation11,12. 
However, subsequent X-ray structures of Imatinib co-crystallized with c-Src revealed a DFG-out conformation 
and an extremely similar binding mode13. A DFG-out conformation has since been observed in many PKs14 and 
a functional role for the in-to-out flip has been proposed10.
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The different selectivity was then proposed to be due to the thermodynamic penalty of the DFG-out state in 
c-Src10,13,15, which prompted an extensive study of this conformational change by computer modeling and simu-
lations16–21. Using state-of-the-art free energy methods, we have proposed that the most important contribution 
to the binding free energy difference of Imatinib to c-Src and c-Abl is, indeed, the stability of the DFG-out con-
formation15, according to a “conformational selection” mechanism. The lower stability of the DFG-out conforma-
tion in c-Src was also confirmed subsequently by a different computational approach21. However, an alternative 
“induced fit” mechanism has been recently proposed based on the interpretation of NMR spectra and stop-flow 
fluorescence22. The data were interpreted to be consistent with a two step process. The authors proposed that 
the two steps are a fast binding of the drug, followed by a slow conformational change. Only the final state, after 
the slow “induced fit” is able to bind Imatinib in the nanomolar range (the initial bound state has Kd in the μM 
range) and the difference in population of this second better-binding state is estimated to determine, on its own, 
a 1000-fold difference in affinity. The nature of the proposed “induced fit” step, however, is still debated, also due 
to an updated model from the same experimental group23, that, more in line with earlier theories24, stresses the 
importance of the conformation of the P-loop (also known as g-loop or glycine-rich loop, Fig. 1). In the case of 
Abl and its drug-resistant mutants, we recently proposed a binding mechanism in which two different confor-
mational changes play a role, providing a consistent interpretation to the recent experimental and computational 
findings25.
Here, to fully characterize the binding mechanism of Imatinib to c-Src, we combine experimental and com-
putational techniques, including μs long unbiased simulations, free energy calculations, high resolution NMR 
experiments and surface plasmon resonance. In so doing, we fully sample the conformational changes associated 
with the binding and shed some light on the relative roles of “conformational selection” and “induced fit” effects.
Our combined spectroscopic and computational results suggest a complex association mechanism. On the 
free energy surface two alternative binding paths coexist in which at room temperature conformational selection 
plays a major role and induced fit a minor one. Conformational changes and meta-stable binding modes con-
tribute to an heterogeneous ensemble of intermediate states. Distant structural elements such as the A-loop, the 
αC, αG and αD helices are involved in coordinated movements thanks to a network of electrostatic interactions 
involving the conserved residues Glu310, Arg409, Asp404 and Lys295 What is more, both simulation and experiments 
agree on a significant role of local unfolding, supporting predictions based on energy landscape theory26,27.
Results
The 2D 1H, 15N-TROSY NMR spectrum of the ligand-free (apo) form of c-Src is shown in SI Fig. S1. Out of 268 
backbone amides, 196 signals are visible, of which 179 (91%) were assigned (BMRB entry 25756). Most of the 
signals corresponding to the A-loop (Figs 1 and 2), the αC helix and some of those corresponding to the αG helix 
are missing.
The absence of signal might be due either to a fast exchange with the solvent or to a slow conformational equi-
librium in the ms-μs time-scale leading to signal broadening beyond detection. As the solvent exchange rate is 
highly dependent on pH, its extent can be inferred by acquiring the spectrum at different pH28. Indeed, increasing 
the pH from 6.4 to 8 causes the disappearance of many signals corresponding to solvent-exposed amide protons, 
as expected from a fast exchange of amino protons with the solvent (SI Fig. S2). On the contrary, decreasing the 
pH to 5 has little effect on the number of visible signals, while significantly reducing the stability of the protein. 
The reduced stability might be in part due to the slightly higher mobility of the DFG motif in the protonated Asp 
state15, as also observed in the case of Abl10 and FGFR114. Thus, a slow conformational equilibrium is expected 
Figure 1. Structure of the kinase domain of c-Src with a detailed view of the DFG motif in the DFG-in apo 
conformation (DFG represented as green sticks; PDB ID: 2SRC). The inset shows the DFG-out Imatinib-
bound form (the DFG and Imatinib are shown as green and blue sticks, respectively; PDB ID: 2OIQ).
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to be the main reason for the absence of many signals in the spectrum recorded at pH 6.4. A similar effect was 
previously reported for the A-loop of the p38 kinase29.
In the TROSY spectrum of the Imatinib-bound c-Src many of the missing signals in the ligand-free form 
become detectable30, in agreement with a substantial alteration of the conformational dynamics upon ligand 
binding (SI Fig. S2).
Fast dynamics of the apo and Imatinib-bound forms. To investigate the effect of Imatinib binding on 
the fast dynamics of c-Src, we performed long (1 μs) MD simulations and NMR relaxation measurements on the 
free and Imatinib-bound forms of c-Src. In Fig. 2 and SI Fig. S4 we report the Cα Root Mean Square Fluctuation 
(RMSF) and the experimentally determined S2 order parameters corresponding to the two forms. While the two 
parameters cover mostly overlapping time-scales, the RMSF, performed on the 1 μs-long trajectories is sensitive 
to changes happening in the ps to hundreds of ns time-scale, while S2 is limited to motions faster than the overall 
tumbling time. A direct comparison of the computed and experimental S2 parameters is reported in SI Fig. S5 and 
shows a good agreement.
In the apo form the largest RMSF is observed for the region of the αG helix, whose orientation fluctuates on a 
time-scale of hundreds of ns. In the bound form lower RMSF values (i.e. a rigidification) are observed for regions 
directly interacting with the drug, as the N-lobe β-sheets and loops, and in particular for the glycine-rich P-loop. 
The hinge region dividing the two lobes, where Imatinib interacts with residues Thr338 and Met341, is also rigidi-
fied, as the central region of the αC helix, near the drug. Surprisingly, the region encompassing the αG helix and 
the nearby loops, albeit not in direct contact with the inhibitor, experiences the most significant rigidification. On 
the contrary, the A-loop and the initial segment of the αC helix are more flexible in the bound form. The average 
conformation of the A-loop in the bound form is similar to that found in the crystal structure of Imatinib-bound 
c-Abl. Throughout both simulations the salt bridge between Glu310 and Arg409, typical for the so-called αC-out 
conformation13, is engaged.
To characterize the motions faster than the overall tumbling, the R1 and R2 15N NMR relaxation rates and the 
1H, 15N heteronuclear NOE of backbone amide nitrogen were measured at 700 MHz. The software TENSOR231, 
was used to analyze the data, yielding the isotropic rotational correlation time τc and the Lipari-Szabo 
sub-nanosecond order parameters (S2)32 (see SI).
Both structures appear to be relatively rigid in the sub-μs time scale with an average S2 of about 0.85 in the apo 
form and 0.87 in the Imatinib-bound form (SI Fig. S3). The only exception is the unstructured N terminus and the 
two loops following the αG-helix that are more flexible (see Fig. 2, again in good agreement with simulation data 
in SI Fig. S5). The general agreement between observed and calculated fast motions can be also seen in the com-
parison of NMR- and simulation-derived S2 parameters. The average deviation is less than 9% (SI Fig. S5). The 
most significant discrepancy is found in the region of the αG helix in c-Src apo form. The NMR data indicates 
lower fluctuations for the visible signals assigned to this region. This is due to the slower character of these 
re-orientation motions that in the simulation happen in the hundreds of ns to μs regime, well beyond the 
NMR-determined tumbling time of 26ns.
Overall, our NMR results do not show large changes in the fast dynamics upon ligand binding. Simulations 
indicate that the rigidification of some regions is compensated by a larger flexibility in other areas. Thus the 
entropy associated to fast motions should not play a major role in the binding mechanism.
Figure 2. c-Src Dynamics, (left) difference in the Cα RMSF (Δrmsf) between the apo and ligand-bound 
forms of c-Src averaged over 1 μs-long MD simulations. Low (blue) values correspond to regions that are 
more rigid (lower RMSF) in the bound form, high (red) values correspond to regions that are more flexible in 
the bound form. (right) Experimentally determined order parameters S2 for the apo (blue) and bound (red) 
forms.
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Instead, we expect that many structural elements, including the αG and αC helix and the A-loop undergo 
large conformational changes in the μs-ms time scale. This is strongly suggested by the values of the R1R2 prod-
uct33, the exchange contribution to relaxation Rex parameter32, the borderline deviations from random coil values 
of the chemical shift index34 (CSI, SI Fig. S3), the many missing signals in the spectrum and the slow conforma-
tional changes observed in the MD simulations.
Changes in the chemical shifts. The changes in chemical shifts due to the binding of Imatinib are reported 
in Fig. 3 and SI Fig. S6. The residues that become visible only in the bound-form are shown in Fig. S6 and include 
many residues of the αC and αG helices as well as the regions closest to Imatinib of αE, αF and αI. The appear-
ance of signals from the αC helix and from two flanking beta strands, indicating a significant change in their 
conformational dynamics, is of particular interest. This helix is known to reposition in the bound form (αC-in) 
through the formation of a salt bridge between Glu310 and Lys29535. The αC helix appears to be essential in mod-
ulating the function of the protein and its movement is connected with the conformational changes of the acti-
vation loop36.
Most of the signals corresponding to the A-loop remain undetectable. A noticeable exception is Asp404, the 
first residue of the DFG motif, whose signal appears in the bound spectrum. As Imatinib stabilizes the DFG-out 
conformation, the appearance of the Asp signal is presumably due to the suppression of the in-out equilibrium 
as in the case of the p38 kinase29. The absence of the signals corresponding to the Phe405 and Gly406 of the DFG in 
the bound form is probably due to some degree of residual motion connected to the A-loop dynamics combined 
with the perturbation of the chemical shift that could be induced by the large magnetic anisotropy of Phe405. This 
hypothesis is supported by the larger B-factors registered for Phe405 and Gly406, compared to Asp404, in the X-ray 
structure of the bound form13.
The appearance of the signal corresponding to Leu472 upon binding is in agreement with MD simulations, 
showing a rigidification of the αG helix. The large magnetic anisotropy of the aromatic rings of Imatinib leads to 
sizeable chemical shift changes. Their sign allows to locate the compound in the crystallographic pose (SI Fig. S6). 
Some of the signals appearing in the bound form correspond to the secondary pocket proposed on the basis of the 
free energy calculations (see below). This indicates rigidification of the area due either to a direct, albeit transient, 
interaction with the drug or to an indirect allosteric effect. A dynamical connection of the two sites would be in 
agreement with an at least partial induced fit effect, as discussed below.
Chemical shift data were compared with those obtained using a DFG-in binding inhibitor, namely the second 
generation tyrosine kinase inhibitor Dasatinib37. Figure 3 shows the perturbations induced by Dasatinib on the 
amide chemical shifts of c-Src, in the same experimental conditions. Also in this case, the most affected region 
is the binding pocket. The main difference between the two is that Imatinib induces a much larger effect on the 
Figure 3. Difference of combined 1H, 15N chemical shift Δδ for Src upon binding of Imatinib (left) and 
Dasatinib (right). Ligands are shown as blue sticks. Residues for which data is not available are shown in dark 
grey.
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nearby beta strands of the N-terminus. This can be easily understood by looking at the crystal structure: in the 
case of Imatinib, the four aromatic moieties (which induce large changes in their surroundings) are placed under-
neath the beta sheet of the N terminus and oriented towards it (see Fig. 3). The signs of the deviations (which 
mostly indicate shielding, see Fig. S6) also support this hypothesis. On the contrary, Dasatibib induces effects 
only on the beta strand 3, to which one of its aromatic rings is close. Also the rigidification of mobile parts of the 
protein seems to be less pronounced in the case of Dasatinib (Fig. S6). A few signals reappear in the presence of 
the drug, but not to the extent found in Imatinib. This is also not too surprising, as Imatibib interacts with a large 
part of the αC helix and contributes to its stabilization. This is not the case with Dasatinib, which points in the 
opposite direction.
Free energy profile and binding mechanism. The free energy profile associated to the (un)-binding of 
Imatinib from c-Src obtained by extensive Parallel Tempering Metadynamics (PT-MetaD)38 simulations is shown 
in Fig. 4.
The profile is characterized by a deep and broad energy basin in which the crystallographic bound state cor-
responds to the deepest minimum (A in Fig. 4). An almost equally stable state (B) is found within the same 
basin. The ligand binding mode is the same in A and B, while the conformation assumed by the residues form-
ing the binding cavity, the A-loop and αG-helix is different (SI Fig. S8). In B, the A-loop assumes a more open 
conformation loosing the contact with the β3-αC loop. The loss of this interaction results in a substantial hinge 
motion, leading to the further opening of the cleft corresponding to the binding site. This opening is necessary 
to the unbinding of Imatinib. Not only the most probable exit path on the Free Energy Surface (FES) involves an 
opening of the cleft, but when we tried to compute the unbinding free energy profile without taking explicitly into 
consideration the hinge motion it leads to unrealistically high energy barriers. The presence of different A-loop 
conformations in the bound state is consistent with the observed broadening and absence of the NMR signals 
corresponding to this region.
The salt bridges formed by the four functionally important charged residues (Lys295, Glu310, Asp404 and Arg409) 
coordinate the movements of the P-loop, the A-loop and the αC helix (SI Fig. S9), as reported in other kinases39,40, 
and allosterically determine the orientation of the αG helix and the formation of an additional helix turn in the 
αF helix (SI Fig. S10).
Beyond the first transition state, which corresponds to Spath ~ 12, an additional metastable minimum is found 
for values of Spath around 15–16 (structure C in Fig. 4). In this conformation, Imatinib has moved away from its 
canonical binding pose and occupies a secondary pocket (sometimes referred to as the “deep pocket”) beneath the 
αC helix in its entirety (SI Fig. S13). The free energy of this secondary minimum is ~4 kcal/mol higher than the 
main minimum, suggesting a population around 1%. While the presence of a second binding pose is not directly 
confirmed by NMR, all the residues that are predicted to interact with Imatinib in this second free energy mini-
mum (SI Fig. S13) also change their dynamical behaviour, as indicated by the appearance of their amide signal in 
the Imatinib-bound NMR spectrum. NMR measurements performed immediately after addition of the drug tend 
to exclude a lifetime longer than minutes.
A transient occupation of this external cavity facilitates the entrance of the drug kinetically, at the very begin-
ning of the recognition process and lowers the free energy penalty of the DFG flip (see below). Recent experi-
ments on Src and Abl22 have suggested a two step binding process, in which a fast binding event is followed by a 
slower conformational rearrangement. While the authors in a later paper23 interpreted the results as suggestive 
Figure 4. Imatinib binding free energy profile along the Spath variable, which defines an optimal association 
coordinate. The most relevant minima and the transition state are labelled and discussed in the text. The area of 
the transition state is represented as a dashed line due to a larger uncertainty. The two profiles in the region 
S 16 to S 27 (secondary pocket to the unbound state) correspond to the conformational selection 
mechanism (red line, “flip-bind”) and to an induced fit mechanism (yellow line, “bind-flip”). The 2D FES in the 
inset shows the dependence of the free energy from the DFG-flip coordinate.
www.nature.com/scientificreports/
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of a fast binding (in the crystallographic pose) followed by an induced-fit mechanism involving the P-loop, their 
data are also explained by our model, which is based both on experimental and computational evidence. Our 
simulations show that the first step is the binding to an external site. The external site has been observed in other 
kinases and is supported by our NMR data. Surprisingly, Imatinib is able to approach the external binding site 
irrespective of the DFG conformation. The first binding is followed by a slower “sliding” into the final pose. This 
latter step involves the drug passing over the DFG and reaching the ATP binding site below the P-loop and both 
a “conformational selection” (red line 4) or “induced fit” (yellow line) mechanisms are possible. The main associ-
ation path (as indicated by the free energy surface) involves a conformational selection mechanism, whereby the 
ligand directly binds to a DFG-out state.
The induced-fit mechanism is less probable than the conformational selection mechanism due to an extra 
energy barrier (yellow line, S 18) that has to be overcome along this alternative association pathway. Clearly, 
mutations of the P-loop (including the“gate-keeper” residue) used to indirectly support the P-loop-based 
induced-fit model23, affect the sliding step25 and might favour the induced-fit mechanism over the conformational 
selection.
The new TS corresponds to structures in which Imatinib is in contact with the Phe405 (see SI). The absolute 
binding free energy, obtained by integrating the free energy of the bound and unbound basin41, is around 
− 8 kcal/mol for the “induced fit” path. In the case of the “conformational selection” path (in red), one has to add 
to the − 14 kcal/mol the ΔG necessary for the DFG-flip, which is around 6.0 kcal/mol15,21, leading again to a total 
binding ΔG of around − 8 kcal/mol. These values have to be increased by the standard volume correction, 
(amounting to . kcal mol1 5 / ) and possibly slightly decreased by change in the protonation state of Imatinib21. 
The final value of − 7 ± 1 kcal/mol is in striking agreement with the experimental value of − 6.8 kcal/mol obtained 
from the Kd. The error bar takes into account only the uncertainty on the reconstructed free energy profiles dur-
ing the final 100 ns of the PT-metaD sampling. Along the conformational selection mechanism, as soon as the 
ligand comes in contact with the P-loop of the kinase, the DFG-out state is stabilized (red line). By comparing the 
free energy difference associated with the DFG-flip at S = 25 with that obtained for the apo-form15, we observe 
that when Imatinib is in contact with the kinase but not directly with the DFG motif the free energy penalty for 
the flip is decreased of  – kcal mol2 3 /  (Fig. 4).
Our proposed model is not only in agreement with the data recently reported22,23, but it also recapitulates a 
plethora of previous computational and experimental evidence10,15,21 and it is in substantial agreement with the 
binding mechanism proposed for a different DFG-out inhibitors binding to the FGFR1 TK14.
Unbinding kinetics and residence time. We measured the dissociation kinetics by surface plasmon res-
onance (SPR) obtaining at pH 7.4 a dissociation rate between 0.024 and 0.19 s−1 (SI Fig. S14). The main unbinding 
barrier, which corresponds to Spath ~ 12, is predicted by PT-metaD to be ± . kcal mol16 1 5 / . The higher sam-
pling error bar is due to the nature of the PT-metaD algorithm, that samples high-in-energy TS worse than the 
energy minima. Given the importance of getting a barrier height as accurate as possible, we also recomputed the 
unbinding barrier with a different algorithm (multiple-walkers42), and obtained a value that is well within the 
error bar of the previous estimate (16.5 kcal/mol). Given the complex nature of the unbinding mechanism, the 
standard transition state theory is not applicable here, i.e. we expect that the transmission coefficient is much less 
than 1. The unbinding rate was instead obtained by using the accurate but computationally expensive TS-PPTIS 
algorithm43, that combines the estimate of the unbinding ΔG with a transmission coefficient computed inde-
pendently. More than 10000 unbiased MD trajectories where initiated from different interfaces at the barrier 
region. As expected for a complex diffusive process, the transmission coefficient is much smaller than 1, leading 
to a dissociation rate of 0.0114 s−1 (1E-3 to 0.139 s−1, when the sampling error is accounted for). The predicted 
range is in excellent agreement with the experimental one.
A representative structure of the transition state (TS) is reported in SI Fig. S8. Imatinib detaches from the 
hinge region of c-Src, moves closer to the DFG motif and a layer of water molecules intercalates between the com-
pound and the hinge (SI Fig. S11). The most relevant differences are observed for the αG helix, which partially 
unfolds at the TS (SI Fig. S8). This seemingly surprising observation confirms the “cracking” hypothesis, whereby 
relevant conformational transitions are accompanied by local unfolding26. The “cracking” lowers the TS energy by 
increasing the conformational entropy, as reported in the case of the Epidermal Growth Factor Receptor kinase44.
In the case of c-Src, the observed chemical shift indexes for the αC and αD helices also suggest partial unfold-
ing (SI Fig. S12). Remarkably, the effect of local unfolding on the transition state energy has been recently shown 
for the binding of the type-II (DFG-out) drug Ponatinib to the Fibroblast Growth Factor Receptor14. The higher 
entropy attained by the “cracking” is needed to overcome the enthalpic penalty due to the DFG flip, as also 
reported in the case of Abl25.
H/D exchange NMR experiments. To investigate the dynamics on longer time scales and, possibly, fur-
ther confirm that a cracking-like mechanism is involved, we performed H/D exchange NMR experiments and 
determined the protection factors and free energies for local unfolding45 (Fig. 5, SI Methods and SI Fig. S7). The 
values are directly related to the ease of exchange of amide protons with the solvent and give a good estimate of 
the energy needed to locally unfold the structure. Lower values correspond to regions that are (at least transiently) 
solvent exposed and unfolded.
While the C-lobe in both the apo and Imatinib-bound form is mostly folded and rigid, the αD, αG and part of 
the αI helices are a notable exception. Their lower protection factors indicate higher flexibility, in agreement with 
the chemical shift indexes. In presence of Imatinib these helices have an even lower protection factor, consistent 
with the transient unfolding of the αG helix observed in the simulations. As Imatinib is a xenobiotic compound, 
it remains an open question whether “cracking” is also involved in the physiological binding and release of ATP/
www.nature.com/scientificreports/
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ADP. The change in the flexibility of the αI helix is also intriguing, as this structural motif has been recently 
shown to play a key role in the interaction with the SH2 regulatory domain46.
Discussion
The catalytic domain of c-Src assumes a compact and relatively rigid structure in solution. With the exception of 
the N-terminus (whose biological significance is limited in a truncated protein), loops are only slightly more flex-
ible than the elements of secondary structure (in the ps-ns time scales). In the apo form the αC-helix, the A-loop 
and other functionally relevant motifs undergo significant conformational changes on time scales spanning the 
μs-ms range. MD simulations show different conformations of the αC helix, in agreement with the αC-in and 
αC-out conformations captured in different crystal structures35.
The conformational landscape of the αC-helix is altered by the binding of Imatinib, as proven by the computed 
free energy landscape and the appearance of most missing signals in the NMR spectra. On the contrary, the sig-
nals corresponding to the A-loop are not visible neither in the spectra of the apo nor of the ligand-bound forms 
due to conformational heterogeneity. However, the conformations spanned by the apo and bound forms are 
different. Simulations18,19 and crystal structures47,48 hint to an equilibrium between the active and inactive forms.
When Imatinib is bound, steric hindrance prevents the A-loop from assuming a fully extended active form. 
Indeed, the simulations predict an equilibrium between closed and semi-closed A-loop conformations.
The computed binding ΔG is in good agreement with the experiment. The free energy calculations of the 
DFG-in to DFG-out conformational change in presence of Imatinib show that Imatinib can approach the site 
irrespective of the DFG conformation. The main association path involves a conformational selection, with a 
small induced-fit effect, predicted to be  kcal mol2 to 3 / . The balance between the two might change at different 
temperatures due to the different entropic/enthalpic balance.
The induced fit effect is also in agreement with the presence of a second “external” binding pose clearly visible 
in the binding free energy profile and suggested by the change of dynamics of the entire region encompassing the 
binding pathway. A two step binding mode involving an external pose has also been suggested in the literature for 
other PKs49,50 and is consistent with recent NMR experiments22.
Concluding our description of c-Src dynamics is the surprising flexibility of helix αG. This helix, together 
with the flanking loops, is the only one experiencing relevant dynamics in the sub-μs time scale. Over longer 
time scales, the αG appears to correlate with the motion of the A-loop, assuming different orientations as a con-
sequence of its conformational rearrangements, and plays an important role in the binding of Imatinib. What is 
more, the αG helix appears to unfold (“cracking”) at the transition state. The excellent agreement between the pre-
dicted koff with that measured with SPR as well as the changes in the dynamics observed by H/D exchange NMR 
Figure 5. Free energies for local unfolding. The values are derived from the kintr and kexch parameters obtained 
from H/D exchange NMR measurements. Red circles indicate αD and αG, the regions with increased exposure 
to the solvent in the bound structure.
www.nature.com/scientificreports/
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experiments, confirm the role of the αG cracking, providing further evidence for the “cracking” mechanism, 
which was also reported in other kinases14,44.
Taken together, our experimental and in-silico results give a solid and comprehensive picture of the mecha-
nism of binding of the anti-cancer drug Imatinib to c-Src and the ensuing local and long-range dynamics. Both 
local and global conformational changes and transient unfolding impact the overall kinase behavior in response 
to molecular recognition. This detailed information is of great importance to reconcile opposing view held in 
the literature and might help the rational development of Src inhibitors. Indeed, the long-range allosteric effect 
described here, linking the αG to the active site, might be used for the development of innovative allosteric inhib-
itors of this and other tyrosine kinases51.
Methods Summary
The molecular dynamics simulations were performed with ACEMD52, GROMACS53 and the 
Amber99SB*-ILDN54,55 force field. Imatinib was parametrized with GAFF56 on the basis of ab-initio calculations. 
All free energy calculations were performed with PT-metaD using GROMACS53 and the PLUMED plugin57. 
NMR experiments were performed on Bruker Avance 600 MHz, 700 MHz and 1 GHz, the latter equipped with 
cryogenically-cooled triple resonance probe. Protein samples were prepared as in ref. 30 and solvated in 20 mM 
phosphate at pH 6.4, 0.5 M NaCl, 1.0 mM MgCl2, 1 mM TCEP and 0.03% NaN3. NMR Relaxation experiments 
were performed at 700 MHz on a 15N labelled sample. All SPR measurements were performed with a Biacore X 
(GE Healthcare) system. (Full methods in SI).
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